1. Market Research
  2. > Autoimmune Disorders - Pipeline Review, H2 2013

Autoimmune Disorders - Pipeline Review, H2 2013

  • July 2013
  • -
  • Global Markets Direct
  • -
  • 734 pages

Autoimmune Disorders - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Autoimmune Disorders - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Autoimmune Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Autoimmune Disorders. Autoimmune Disorders - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Autoimmune Disorders.
- A review of the Autoimmune Disorders products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Autoimmune Disorders pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Autoimmune Disorders.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Autoimmune Disorders pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Autoimmune Disorders - Pipeline Review, H2 2013
Table of Contents
Table of Contents 2
Introduction 15
Autoimmune Disorders Overview 16
Therapeutics Development 17
Autoimmune Disorders Therapeutics under Development by Companies 19
Autoimmune Disorders Therapeutics under Investigation by Universities/Institutes 52
Late Stage Products 56
Mid Clinical Stage Products 57
Early Clinical Stage Products 58
Discovery and Pre-Clinical Stage Products 59
Autoimmune Disorders Therapeutics - Products under Development by Companies 60
Autoimmune Disorders Therapeutics - Products under Investigation by Universities/Institutes 115
Companies Involved in Autoimmune Disorders Therapeutics Development 119
Autoimmune Disorders - Therapeutics Assessment 465
Drug Profiles 473
Autoimmune Disorders Therapeutics - Drug Profile Updates 572
Autoimmune Disorders Therapeutics - Discontinued Products 650
Autoimmune Disorders Therapeutics - Dormant Products 664
Autoimmune Disorders - Product Development Milestones 708
Appendix 720

List of Tables

Number of Products Under Development for Autoimmune Disorders, H2 2013 30
Products under Development for Autoimmune Disorders - Comparative Analysis, H2 2013 31
Number of Products under Development by Companies, H2 2013 33
Number of Products under Development by Companies, H2 2013 (Contd..1) 34
Number of Products under Development by Companies, H2 2013 (Contd..2) 35
Number of Products under Development by Companies, H2 2013 (Contd..3) 36
Number of Products under Development by Companies, H2 2013 (Contd..4) 37
Number of Products under Development by Companies, H2 2013 (Contd..5) 38
Number of Products under Development by Companies, H2 2013 (Contd..6) 39
Number of Products under Development by Companies, H2 2013 (Contd..7) 40
Number of Products under Development by Companies, H2 2013 (Contd..8) 41
Number of Products under Development by Companies, H2 2013 (Contd..9) 42
Number of Products under Development by Companies, H2 2013 (Contd..10) 43
Number of Products under Development by Companies, H2 2013 (Contd..11) 44
Number of Products under Development by Companies, H2 2013 (Contd..12) 45
Number of Products under Development by Companies, H2 2013 (Contd..13) 46
Number of Products under Development by Companies, H2 2013 (Contd..14) 47
Number of Products under Development by Companies, H2 2013 (Contd..15) 48
Number of Products under Development by Companies, H2 2013 (Contd..16) 49
Number of Products under Development by Companies, H2 2013 (Contd..17) 50
Number of Products under Development by Companies, H2 2013 (Contd..18) 51
Number of Products under Development by Companies, H2 2013 (Contd..19) 52
Number of Products under Development by Companies, H2 2013 (Contd..20) 53
Number of Products under Development by Companies, H2 2013 (Contd..21) 54
Number of Products under Development by Companies, H2 2013 (Contd..22) 55
Number of Products under Development by Companies, H2 2013 (Contd..23) 56
Number of Products under Development by Companies, H2 2013 (Contd..24) 57
Number of Products under Development by Companies, H2 2013 (Contd..25) 58
Number of Products under Development by Companies, H2 2013 (Contd..26) 59
Number of Products under Development by Companies, H2 2013 (Contd..27) 60
Number of Products under Development by Companies, H2 2013 (Contd..28) 61
Number of Products under Development by Companies, H2 2013 (Contd..29) 62
Number of Products under Development by Companies, H2 2013 (Contd..30) 63
Number of Products under Development by Companies, H2 2013 (Contd..31) 64
Number of Products under Investigation by Universities/Institutes, H2 2013 66
Number of Products under Investigation by Universities/Institutes, H2 2013 (Contd..1) 67
Number of Products under Investigation by Universities/Institutes, H2 2013 (Contd..2) 68
Comparative Analysis by Late Stage Development, H2 2013 69
Comparative Analysis by Mid Clinical Stage Development, H2 2013 70
Comparative Analysis by Early Clinical Stage Development, H2 2013 71
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 72
Products under Development by Companies, H2 2013 73
Products under Development by Companies, H2 2013 (Contd..1) 74
Products under Development by Companies, H2 2013 (Contd..2) 75
Products under Development by Companies, H2 2013 (Contd..3) 76
Products under Development by Companies, H2 2013 (Contd..4) 77
Products under Development by Companies, H2 2013 (Contd..5) 78
Products under Development by Companies, H2 2013 (Contd..6) 79
Products under Development by Companies, H2 2013 (Contd..7) 80
Products under Development by Companies, H2 2013 (Contd..8) 81
Products under Development by Companies, H2 2013 (Contd..9) 82
Products under Development by Companies, H2 2013 (Contd..10) 83
Products under Development by Companies, H2 2013 (Contd..11) 84
Products under Development by Companies, H2 2013 (Contd..12) 85
Products under Development by Companies, H2 2013 (Contd..13) 86
Products under Development by Companies, H2 2013 (Contd..14) 87
Products under Development by Companies, H2 2013 (Contd..15) 88
Products under Development by Companies, H2 2013 (Contd..16) 89
Products under Development by Companies, H2 2013 (Contd..17) 90
Products under Development by Companies, H2 2013 (Contd..18) 91
Products under Development by Companies, H2 2013 (Contd..19) 92
Products under Development by Companies, H2 2013 (Contd..20) 93
Products under Development by Companies, H2 2013 (Contd..21) 94
Products under Development by Companies, H2 2013 (Contd..22) 95
Products under Development by Companies, H2 2013 (Contd..23) 96
Products under Development by Companies, H2 2013 (Contd..24) 97
Products under Development by Companies, H2 2013 (Contd..25) 98
Products under Development by Companies, H2 2013 (Contd..26) 99
Products under Development by Companies, H2 2013 (Contd..27) 100
Products under Development by Companies, H2 2013 (Contd..28) 101
Products under Development by Companies, H2 2013 (Contd..29) 102
Products under Development by Companies, H2 2013 (Contd..30) 103
Products under Development by Companies, H2 2013 (Contd..31) 104
Products under Development by Companies, H2 2013 (Contd..32) 105
Products under Development by Companies, H2 2013 (Contd..33) 106
Products under Development by Companies, H2 2013 (Contd..34) 107
Products under Development by Companies, H2 2013 (Contd..35) 108
Products under Development by Companies, H2 2013 (Contd..36) 109
Products under Development by Companies, H2 2013 (Contd..37) 110
Products under Development by Companies, H2 2013 (Contd..38) 111
Products under Development by Companies, H2 2013 (Contd..39) 112
Products under Development by Companies, H2 2013 (Contd..40) 113
Products under Development by Companies, H2 2013 (Contd..41) 114
Products under Development by Companies, H2 2013 (Contd..42) 115
Products under Development by Companies, H2 2013 (Contd..43) 116
Products under Development by Companies, H2 2013 (Contd..44) 117
Products under Development by Companies, H2 2013 (Contd..45) 118
Products under Development by Companies, H2 2013 (Contd..46) 119
Products under Development by Companies, H2 2013 (Contd..47) 120
Products under Development by Companies, H2 2013 (Contd..48) 121
Products under Development by Companies, H2 2013 (Contd..49) 122
Products under Development by Companies, H2 2013 (Contd..50) 123
Products under Development by Companies, H2 2013 (Contd..51) 124
Products under Development by Companies, H2 2013 (Contd..52) 125
Products under Development by Companies, H2 2013 (Contd..53) 126
Products under Development by Companies, H2 2013 (Contd..54) 127
Products under Investigation by Universities/Institutes, H2 2013 128
Products under Investigation by Universities/Institutes, H2 2013 (Contd..1) 129
Products under Investigation by Universities/Institutes, H2 2013 (Contd..2) 130
Products under Investigation by Universities/Institutes, H2 2013 (Contd..3) 131
Alcon, Inc., H2 2013 132
Bristol-Myers Squibb Company, H2 2013 133
Genzyme Corporation, H2 2013 134
Baxter International Inc., H2 2013 135
Johnson and Johnson, H2 2013 136
Boehringer Ingelheim GmbH, H2 2013 137
F. Hoffmann-La Roche Ltd., H2 2013 138
Kyowa Hakko Kirin Co., Ltd., H2 2013 139
Biogen Idec Inc., H2 2013 140
Shionogi and Co., Ltd., H2 2013 141
Valeant Pharmaceuticals International, H2 2013 142
Amgen Inc., H2 2013 143
Antares Pharma, Inc., H2 2013 144
Sanofi-Aventis, H2 2013 145
AstraZeneca PLC, H2 2013 146
Eli Lilly and Company, H2 2013 147
GlaxoSmithKline plc, H2 2013 148
Echo Therapeutics, Inc., H2 2013 149
Genentech, Inc., H2 2013 150
Inovio Biomedical Corporation, H2 2013 151
MedImmune LLC, H2 2013 152
Isis Pharmaceuticals, Inc., H2 2013 153
Biotest AG, H2 2013 154
Merck and Co., Inc., H2 2013 155
Stiefel Laboratories, Inc., H2 2013 156
Santen Pharmaceutical Co., Ltd., H2 2013 157
Ablynx, H2 2013 158
AbGenomics International, Inc., H2 2013 159
Emergent BioSolutions Inc., H2 2013 160
Novo Nordisk A/S, H2 2013 161
Cytokine PharmaSciences, Inc., H2 2013 162
Infinity Pharmaceuticals, Inc., H2 2013 163
Plexxikon Inc., H2 2013 164
XenoPort, Inc., H2 2013 165
ViaCord, H2 2013 166
BioLineRx, Ltd., H2 2013 167
ApoPharma, H2 2013 168
FibroGen, Inc., H2 2013 169
arGentis Pharmaceuticals, LLC, H2 2013 170
Reliance Life Sciences Pvt. Ltd., H2 2013 171
Piramal Healthcare Limited, H2 2013 172
MediGene AG, H2 2013 173
Celltrion, Inc., H2 2013 174
Apitope International NV, H2 2013 175
Nycomed International Management GmbH, H2 2013 176
TiGenix NV, H2 2013 177
Pacira Pharmaceuticals, Inc., H2 2013 178
Novartis AG, H2 2013 179
Isotechnika Pharma Inc., H2 2013 180
Samyang Corporation, H2 2013 181
Actelion Ltd, H2 2013 182
Astellas Pharma Inc., H2 2013 183
Biocon Limited, H2 2013 184
BioMarin Pharmaceutical Inc., H2 2013 185
Chugai Pharmaceutical Co. Ltd, H2 2013 186
Daewoong Pharmaceutical Co., Ltd., H2 2013 187
Eisai Co., Ltd., H2 2013 188
Elan Corporation, plc, H2 2013 189
Gedeon Richter Plc., H2 2013 190
Glenmark Pharmaceuticals Ltd., H2 2013 191
GTC Biotherapeutics, Inc., H2 2013 192
Japan Tobacco Inc., H2 2013 193
LEO Pharma A/S, H2 2013 194
Ono Pharmaceutical Co., Ltd., H2 2013 195
Pfizer Inc., H2 2013 196
Ranbaxy Laboratories Limited, H2 2013 197
Rigel Pharmaceuticals, Inc., H2 2013 198
Santarus, Inc., H2 2013 199
Teva Pharmaceutical Industries Limited, H2 2013 200
Toyama Chemical Co. Ltd, H2 2013 201
UCB Group, H2 2013 202
Zydus Cadila Healthcare Limited, H2 2013 204
Cell Therapeutics, Inc., H2 2013 205
Genmab A/S, H2 2013 206

List of Figures

Number of Products under Development for Autoimmune Disorders, H2 2013 30
Products under Development for Autoimmune Disorders - Comparative Analysis, H2 2013 31
Products under Development by Companies, H2 2013 32
Products under Investigation by Universities/Institutes, H2 2013 65
Late Stage Products, H2 2013 69
Mid Clinical Stage Products, H2 2013 70
Early Clinical Stage Products, H2 2013 71
Discovery and Pre-Clinical Stage Products, H2 2013 72
Assessment by Monotherapy Products, H2 2013 478
Assessment by Combination Products, H2 2013 479
Assessment by Route of Administration, H2 2013 480
Assessment by Stage and Route of Administration, H2 2013 481
Assessment by Molecule Type, H2 2013 483
Assessment by Stage and Molecule Type, H2 2013 484

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.